1. Zanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant.
- Author
-
Euzen V, Xhaard A, Berreira-Ibraim S, Deville L, Quentin A, De Lima Prata PH, Gournay V, Prot M, Rahou Y, Barbet M, Mercier-Delarue S, Peffault De La Tour R, Simon-Loriere E, and Legoff J
- Subjects
- Humans, Coronavirus OC43, Human drug effects, Coronavirus OC43, Human genetics, Drug Resistance, Viral genetics, Influenza A virus drug effects, Influenza A virus genetics, Coronavirus Infections drug therapy, Coronavirus Infections virology, Immunocompromised Host, Male, Drug Therapy, Combination, Middle Aged, Virus Shedding drug effects, Virus Replication drug effects, Female, Zanamivir therapeutic use, Zanamivir pharmacology, Hematopoietic Stem Cell Transplantation adverse effects, Antiviral Agents therapeutic use, Antiviral Agents pharmacology, Influenza, Human drug therapy, Influenza, Human virology, Pyridones therapeutic use, Dibenzothiepins therapeutic use, Morpholines therapeutic use, Triazines therapeutic use, Triazines pharmacology
- Abstract
Objectives: Immunocompromised patients may experience prolonged shedding of influenza virus potentially leading to severe infections. Alternatives to monotherapy with neuraminidase inhibitors should be evaluated to entirely suppress viral replication and prevent drug-resistant mutations., Methods: We investigated the clinical and virological evolution in a case of persistent influenza A and human coronavirus OC43 (HCoV-OC43) coinfection in a hematopoietic stem cell transplant recipient after different therapeutic strategies., Results: Successive oseltamivir and zanamivir monotherapies failed to control both infections, with positive results persisting for over 110 days each. This led to the emergence of highly resistant oseltamivir strains due to neuraminidase mutations (E119V and R292K) followed by a deletion (del245-248), while maintaining sensitivity to zanamivir. The intra-host viral diversity data showed that the treatments impacted viral diversity of influenza virus, but not of HCoV-OC43. Considering the patient's underlying condition and the impact of prolonged viral shedding on pulmonary function, eradicating the influenza virus was necessary. A 10-day regimen combining zanamivir and baloxavir-marboxil effectively controlled influenza virus replication and was associated with the clearance of HCoV-OC43, finally resulting in comprehensive respiratory recovery., Conclusion: These observations underscore the importance of further investigating combination treatments as the primary approach to achieve influenza eradication in immunocompromised patients., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF